Matthew Wein

CIK: 0002009713

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (63.6%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (36.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

MGX

Metagenomi Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

MGX
Metagenomi Therapeutics, Inc.
Sep 8, 2026
Sale(S)
Direct
358 shares at avg. $1.16$414.707
MGX
Metagenomi Therapeutics, Inc.
Jun 5, 2026
Sale(S)
Direct
558 shares at avg. $1.30$724.842
MGX
Metagenomi Therapeutics, Inc.
Apr 1, 2026
Award(A)
Direct
11K shares-
MGX
Metagenomi Therapeutics, Inc.
Mar 5, 2026
Sale(S)
Direct
482 shares at avg. $1.60$771.2
MGX
Metagenomi, Inc.
Dec 5, 2025
Sale(S)
Direct
199 shares at avg. $1.77$352.608
MGX
Metagenomi, Inc.
Dec 1, 2025
Award(A)
Direct
96K shares at avg. $1.60$154K
MGX
Metagenomi, Inc.
Sep 5, 2025
Sale(S)
Direct
199 shares at avg. $1.81$360.19
MGX
Metagenomi, Inc.
Jun 6, 2025
Sale(S)
Direct
199 shares at avg. $1.75$348.25
MGX
Metagenomi, Inc.
Apr 1, 2025
Award(A)
Direct
3.8K shares-
MGX
Metagenomi, Inc.
Apr 1, 2025
Award(A)
Direct
3.7K shares-
MGX
Metagenomi, Inc.
Mar 5, 2025
Sale(S)
Direct
930 shares at avg. $1.87$2K

		Type	Shares	Price		Ownership
Sep 8, 2026	MGX Metagenomi Therapeutics, Inc.	Sale(S)	358	$1.16	$415	Direct
Jun 5, 2026	MGX Metagenomi Therapeutics, Inc.	Sale(S)	558	$1.30	$725	Direct
Apr 1, 2026	MGX Metagenomi Therapeutics, Inc.	Award(A)	11,000	-	$0	Direct
Mar 5, 2026	MGX Metagenomi Therapeutics, Inc.	Sale(S)	482	$1.60	$771	Direct
Dec 5, 2025	MGX Metagenomi, Inc.	Sale(S)	199	$1.77	$353	Direct
Dec 1, 2025	MGX Metagenomi, Inc.	Award(A)	96,000	$1.60	$153,600	Direct
Sep 5, 2025	MGX Metagenomi, Inc.	Sale(S)	199	$1.81	$360	Direct
Jun 6, 2025	MGX Metagenomi, Inc.	Sale(S)	199	$1.75	$348	Direct
Apr 1, 2025	MGX Metagenomi, Inc.	Award(A)	3,775	-	-	Direct
Apr 1, 2025	MGX Metagenomi, Inc.	Award(A)	3,650	-	-	Direct
Mar 5, 2025	MGX Metagenomi, Inc.	Sale(S)	930	$1.87	$1,744	Direct

1-11 of 11 transactions

About Wein Matthew

Wein Matthew (SEC CIK 0002009713) files insider reports with the SEC as Officer of Metagenomi Therapeutics, Inc. (MGX).

Signal8 holds 9 ownership filings by Wein Matthew, all Form 4s, filed between Mar 7, 2025 and Sep 10, 2026. Those filings report 11 transactions, from Mar 5, 2025 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Wein Matthew's filings is in EMERYVILLE, CA.

Recent filings by Wein Matthew

Sep 8, 2026: Open-market sale of MGX shares (Form 4, code S).
Jun 5, 2026: Open-market sale of MGX shares (Form 4, code S).
Apr 1, 2026: Grant or award of MGX shares (Form 4, code A).
Mar 5, 2026: Open-market sale of MGX shares (Form 4, code S).
Dec 5, 2025: Open-market sale of MGX shares (Form 4, code S).

Other insiders filing for Metagenomi Therapeutics, Inc. (MGX)

Reid Laurence, Director
Irish Jian
Wapnick Pamela, Chief Financial Officer
Dere Willard H, Director
BJERKHOLT ERIC, Director
Eckhardt Juergen, Director

How to read Form 4 transaction codes